Tirzepatide – 50mg
High-Strength Dual-Action Research Peptide for Advanced Research Applications
Zenovus Sciences Tirzepatide 50MG is a high-strength research peptide formulated for professional laboratory and preclinical research applications. Featuring dual GIP/GLP-1 receptor activity, this research compound is presented as a lyophilized peptide preparation intended for researchers investigating incretin signaling, metabolic pathways, receptor activity, and related areas of scientific research.
Couldn't load pickup availability
Research Background
Tirzepatide has been extensively investigated through clinical and scientific research programs exploring the interaction between GIP and GLP-1 receptor pathways. Research into this dual-receptor mechanism has contributed to a broader understanding of incretin signaling, metabolic regulation, glucose homeostasis, and energy balance. As a well-characterized dual incretin receptor agonist, tirzepatide continues to serve as an important reference compound for researchers studying GIP/GLP-1 receptor activity and the development of next-generation peptide-based research compounds.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 50mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2023788-19-2
- Molecular Weight: 4813.5 Da
Certificate of Analysis
Each Zenovus Sciences Tirzepatide batch is subject to quality-control testing. Analytical documentation, including applicable HPLC and mass spectrometry results, may be provided with the product or made available upon request.
For research and laboratory use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.